Please login to the form below

Not currently logged in
Email:
Password:

Shire experiences sales growth thanks to ADHD drug

Shire reported a rise in sales and revenues on the back of the success of new drugs such as the much-criticised medicine, Vyvanse, on February 21.

Shire reported a rise in sales and revenues on the back of the success of new drugs such as the much-criticised medicine, Vyvanse, on February 21.

Investors' concerns over the attention deficit and hyperactivity disorder (ADHD) treatment were alleviated as Shire reported a 41 per cent increase in sales at the end of 2007.

Total company revenues were up by 36 per cent of which 23 per cent was thanks to the sale of new medications.

Matthew Emmens, chief executive officer of Shire, said: "The launch of Vyvanse continues to progress well and we are confident about the medication's future growth supported by new clinical studies."

US-based researchers reported last year that ADHD drugs could stunt growth and did not improve behaviour over a sustained period of time [PMLive November 2007].

Emmens said: ëThe acquisition of New River Pharmaceuticals (April 2007) gave us full ownership and control of Vyvanse and this new generation ADHD treatment is establishing itself in the US, where it has already gained a market share of 6 per cent.î

22nd February 2008

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Synergy Vision

Synergy Vision believe in delivering medical communications that make a difference to healthcare professionals and patients. Our synergy of pharma...

Latest intelligence

Theresa Heggie
Alnylam’s big moment: bringing groundbreaking RNAi drugs to Europe
Theresa Heggie talks about the biotech’s 16-year path to market, and the promise of its ‘gene silencing’ medicines...
patients
Retaining reader value in plain language summaries of clinical studies
Balancing the risk of misinterpretation with the public’s ability to understand simplified plain-language summaries...
Can we talk about the ego-bias and chemicals influencing your target audience’s behaviour?
Over the Summer, the Page & Page team became fascinated by two books on this very subject. Two books from one author, Dean Burnett, an eminent neuroscientist, lecturing at Cardiff...

Infographics